inclusion criteria * health personnel working at inr lgii or incmnsz who wish to participate in the study and sign the informed consent. * over 18 and under 60 years of age, both genders. * contacting with suspected or confirmed sars-cov-2 infection. * normal electrocardiogram. exclusion criteria * positive quantitative reverse transcriptase-polymerase chain reaction (qrt-pcr) test for sars-cov-2 at the time of inclusion. * panel of igg or igm antibodies positive for sars-cov-2 at the time of inclusion. * development of respiratory symptoms suspicious of sars-cov-2 infection during the first 7 days after treatment is initiated, confirmed by qrt-pcr and igg or igm antibodies postiver for sars-cov-2. * history of allergies to any hydroxychloroquine or bromhexine related compound or medication. * use of immunosuppressors for any reason. * history of bone marrow transplant. * known glucose-6-phosphate dehydrogenase deficiency. * chronic kidney disease or glomerular filtration \<20ml/min. * use of other drugs with reported pharmacological interactions (i.e., digitalis, flecainide, amiodarone, procainamide, or propafenone). * history of long qt syndrome. * electrocardiogram with qtc\>500 msec. * pregnant or breastfeeding personnel. * epilepsy. * known liver disease. * personnel who have received the covid-19 vaccine elimination criteria * personnel who decide to leave the study for any reason not related to adverse events. * personnel with incomplete information on the primary outcome (qrt-pcr for sars-cov-2). * personnel who are relocated to work in another institution. * personnel who do not wish to participate in the study

inclusion criteria * health personnel working at inr lgii or incmnsz who wish to participate in the study and sign the informed consent. * over 18 and under 60 years of age, both genders. * contacting with suspected or confirmed sars-cov-2 infection. * normal electrocardiogram. exclusion criteria * positive quantitative reverse transcriptase-polymerase chain reaction (qrt-pcr) test for sars-cov-2 at the time of inclusion. * panel of igg or igm antibodies positive for sars-cov-2 at the time of inclusion. * development of respiratory symptoms suspicious of sars-cov-2 infection during the first 7 days after treatment is initiated, confirmed by qrt-pcr and igg or igm antibodies postiver for sars-cov-2. * history of allergies to any hydroxychloroquine or bromhexine related compound or medication. * use of immunosuppressors for any reason. * history of bone marrow transplant. * known glucose-6-phosphate dehydrogenase deficiency. * chronic kidney disease or glomerular filtration \<20ml/min. * use of other drugs with reported pharmacological interactions (i.e., digitalis, flecainide, amiodarone, procainamide, or propafenone). * history of long qt syndrome. * electrocardiogram with qtc\>500 msec. * pregnant or breastfeeding personnel. * epilepsy. * known liver disease. * personnel who have received the covid-19 vaccine elimination criteria * personnel who decide to leave the study for any reason not related to adverse events. * personnel with incomplete information on the primary outcome (qrt-pcr for sars-cov-2). * personnel who are relocated to work in another institution. * personnel who do not wish to participate in the study

inclusion criteria - health personnel working at inr lgii or incmnsz who wish to participate in the study and sign the informed consent. - over 18 and under 60 years of age, both genders. - contacting with suspected or confirmed sars-cov-2 infection. - normal electrocardiogram. exclusion criteria - positive quantitative reverse transcriptase-polymerase chain reaction (qrt-pcr) test for sars-cov-2 at the time of inclusion. - panel of igg or igm antibodies positive for sars-cov-2 at the time of inclusion. - development of respiratory symptoms suspicious of sars-cov-2 infection during the first 7 days after treatment is initiated, confirmed by qrt-pcr and igg or igm antibodies postiver for sars-cov-2. - history of allergies to any hydroxychloroquine or bromhexine related compound or medication. - use of immunosuppressors for any reason. - history of bone marrow transplant. - known glucose-6-phosphate dehydrogenase deficiency. - chronic kidney disease or glomerular filtration <20ml/min. - use of other drugs with reported pharmacological interactions (i.e., digitalis, flecainide, amiodarone, procainamide, or propafenone). - history of long qt syndrome. - electrocardiogram with qtc>500 msec. - pregnant or breastfeeding personnel. - epilepsy. - known liver disease. - personnel who have received the covid-19 vaccine elimination criteria - personnel who decide to leave the study for any reason not related to adverse events. - personnel with incomplete information on the primary outcome (qrt-pcr for sars-cov-2). - personnel who are relocated to work in another institution. - personnel who do not wish to participate in the study

inclusion criteria - health personnel working at inr lgii or incmnsz who wish to participate in the study and sign the informed consent. - over 18 and under 60 years of age, both genders. - contacting with suspected or confirmed sars-cov-2 infection. - normal electrocardiogram. exclusion criteria - positive quantitative reverse transcriptase-polymerase chain reaction (qrt-pcr) test for sars-cov-2 at the time of inclusion. - panel of igg or igm antibodies positive for sars-cov-2 at the time of inclusion. - development of respiratory symptoms suspicious of sars-cov-2 infection during the first 7 days after treatment is initiated, confirmed by qrt-pcr and igg or igm antibodies postiver for sars-cov-2. - history of allergies to any hydroxychloroquine or bromhexine related compound or medication. - use of immunosuppressors for any reason. - history of bone marrow transplant. - known glucose-6-phosphate dehydrogenase deficiency. - chronic kidney disease or glomerular filtration <20ml/min. - use of other drugs with reported pharmacological interactions (i.e., digitalis, flecainide, amiodarone, procainamide, or propafenone). - history of long qt syndrome. - electrocardiogram with qtc>500 msec. - pregnant or breastfeeding personnel. - epilepsy. - known liver disease. - personnel who have received the covid-19 vaccine elimination criteria - personnel who decide to leave the study for any reason not related to adverse events. - personnel with incomplete information on the primary outcome (qrt-pcr for sars-cov-2). - personnel who are relocated to work in another institution. - personnel who do not wish to participate in the study

inclusion criteria - health personnel working at inr lgii or incmnsz who wish to participate in the study and sign the informed consent. - over 18 and under 60 years of age, both genders. - contacting with suspected or confirmed sars-cov-2 infection. - normal electrocardiogram. exclusion criteria - positive quantitative reverse transcriptase-polymerase chain reaction (qrt-pcr) test for sars-cov-2 at the time of inclusion. - panel of igg or igm antibodies positive for sars-cov-2 at the time of inclusion. - development of respiratory symptoms suspicious of sars-cov-2 infection during the first 7 days after treatment is initiated, confirmed by qrt-pcr and igg or igm antibodies postiver for sars-cov-2. - health personnel with comorbidities such as diabetes, hypertension, autoimmune diseases (i.e., porphyria, psoriasis, systemic lupus erythematosus), obesity (defined as body mass index ≥30), cardiovascular diseases, respiratory diseases (such as asthma, chronic bronchitis, idiopathic pulmonary fibrosis). - history of allergies to any hydroxychloroquine or bromhexine related compound or medication. - use of immunosuppressors for any reason. - history of bone marrow transplant. - known glucose-6-phosphate dehydrogenase deficiency. - chronic kidney disease or glomerular filtration <20ml/min. - use of other drugs with reported pharmacological interactions (i.e., digitalis, flecainide, amiodarone, procainamide, or propafenone). - history of long qt syndrome. - electrocardiogram with qtc>500 msec. - pregnant or breastfeeding personnel. - epilepsy. - known liver disease. - personnel who have received the covid-19 vaccine elimination criteria - personnel who decide to leave the study for any reason not related to adverse events. - personnel with incomplete information on the primary outcome (qrt-pcr for sars-cov-2). - personnel who are relocated to work in another institution. - personnel who do not wish to participate in the study

inclusion criteria - health personnel working at inr lgii or incmnsz who wish to participate in the study and sign the informed consent. - over 18 and under 60 years of age, both genders. - contacting with suspected or confirmed sars-cov-2 infection. - normal electrocardiogram. exclusion criteria - positive quantitative reverse transcriptase-polymerase chain reaction (qrt-pcr) test for sars-cov-2 at the time of inclusion. - panel of igg or igm antibodies positive for sars-cov-2 at the time of inclusion. - development of respiratory symptoms suspicious of sars-cov-2 infection during the first 7 days after treatment is initiated, confirmed by qrt-pcr and igg or igm antibodies postiver for sars-cov-2. - health personnel with comorbidities such as diabetes, hypertension, autoimmune diseases (i.e., porphyria, psoriasis, systemic lupus erythematosus), obesity (defined as body mass index ≥30), cardiovascular diseases, respiratory diseases (such as asthma, chronic bronchitis, idiopathic pulmonary fibrosis). - history of allergies to any hydroxychloroquine or bromhexine related compound or medication. - use of immunosuppressors for any reason. - history of bone marrow transplant. - known glucose-6-phosphate dehydrogenase deficiency. - chronic kidney disease or glomerular filtration <20ml/min. - use of other drugs with reported pharmacological interactions (i.e., digitalis, flecainide, amiodarone, procainamide, or propafenone). - history of long qt syndrome. - electrocardiogram with qtc>500 msec. - pregnant or breastfeeding personnel. - epilepsy. - known liver disease. - personnel who have received the covid-19 vaccine elimination criteria - personnel who decide to leave the study for any reason not related to adverse events. - personnel with incomplete information on the primary outcome (qrt-pcr for sars-cov-2). - personnel who are relocated to work in another institution. - personnel who do not wish to participate in the study

inclusion criteria: • health care workers with high exposure to covid-19 patients

inclusion criteria: • health care workers with high exposure to covid-19 patients